$27.1
3.39%
Downside
Day's Volatility :4.66%
Upside
1.31%
82.29%
Downside
52 Weeks Volatility :86.22%
Upside
22.22%
Period | Caredx, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 78.17% | 5.1% | 0.0% |
6 Months | 126.97% | 4.9% | 0.0% |
1 Year | 228.09% | 16.6% | 0.0% |
3 Years | -63.07% | 13.2% | -22.3% |
Market Capitalization | 1.4B |
Book Value | $5.03 |
Earnings Per Share (EPS) | -2.98 |
PEG Ratio | -0.12 |
Wall Street Target Price | 32.71 |
Profit Margin | -53.73% |
Operating Margin TTM | -4.37% |
Return On Assets TTM | -9.81% |
Return On Equity TTM | -47.66% |
Revenue TTM | 297.1M |
Revenue Per Share TTM | 5.62 |
Quarterly Revenue Growth YOY | 31.3% |
Gross Profit TTM | 209.6M |
EBITDA | -62.4M |
Diluted Eps TTM | -2.98 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.25 |
EPS Estimate Next Year | 0.35 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.11 |
What analysts predicted
Upside of 20.7%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 76.6M | ↑ 58.45% |
Net Income | -46.8M | ↓ 15.71% |
Net Profit Margin | -61.06% | ↑ 53.73% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 127.1M | ↑ 65.95% |
Net Income | -22.0M | ↓ 53.02% |
Net Profit Margin | -17.29% | ↑ 43.77% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 192.2M | ↑ 51.25% |
Net Income | -18.7M | ↓ 14.81% |
Net Profit Margin | -9.74% | ↑ 7.55% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 296.4M | ↑ 54.22% |
Net Income | -30.7M | ↑ 63.85% |
Net Profit Margin | -10.34% | ↓ 0.6% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 321.8M | ↑ 8.57% |
Net Income | -76.6M | ↑ 149.86% |
Net Profit Margin | -23.81% | ↓ 13.47% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 280.3M | ↓ 12.89% |
Net Income | -190.3M | ↑ 148.37% |
Net Profit Margin | -67.88% | ↓ 44.07% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 77.3M | ↓ 6.22% |
Net Income | -23.7M | ↑ 29.57% |
Net Profit Margin | -30.74% | ↓ 8.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 70.3M | ↓ 9.01% |
Net Income | -25.0M | ↑ 5.07% |
Net Profit Margin | -35.49% | ↓ 4.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 67.2M | ↓ 4.42% |
Net Income | -23.5M | ↓ 5.88% |
Net Profit Margin | -34.95% | ↑ 0.54% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 65.6M | ↓ 2.42% |
Net Income | -118.1M | ↑ 402.86% |
Net Profit Margin | -180.11% | ↓ 145.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 72.0M | ↑ 9.88% |
Net Income | -16.7M | ↓ 85.89% |
Net Profit Margin | -23.12% | ↑ 156.99% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 92.3M | ↑ 28.07% |
Net Income | -1.4M | ↓ 91.63% |
Net Profit Margin | -1.51% | ↑ 21.61% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 130.7M | ↑ 56.4% |
Total Liabilities | 34.8M | ↓ 61.16% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 151.7M | ↑ 16.1% |
Total Liabilities | 52.7M | ↑ 51.68% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 368.5M | ↑ 142.86% |
Total Liabilities | 90.8M | ↑ 72.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 566.6M | ↑ 53.76% |
Total Liabilities | 100.7M | ↑ 10.91% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 543.0M | ↓ 4.17% |
Total Liabilities | 112.1M | ↑ 11.25% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 484.6M | ↓ 10.75% |
Total Liabilities | 223.3M | ↑ 99.22% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 528.2M | ↓ 2.72% |
Total Liabilities | 108.2M | ↓ 3.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 514.8M | ↓ 2.54% |
Total Liabilities | 109.6M | ↑ 1.3% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 501.2M | ↓ 2.65% |
Total Liabilities | 107.0M | ↓ 2.34% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 484.6M | ↓ 3.31% |
Total Liabilities | 223.3M | ↑ 108.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 452.4M | ↓ 6.65% |
Total Liabilities | 196.2M | ↓ 12.14% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 466.8M | ↑ 3.18% |
Total Liabilities | 202.1M | ↑ 3.02% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.0M | ↓ 71.99% |
Investing Cash Flow | -7.9M | ↑ 28.63% |
Financing Cash Flow | 50.3M | ↑ 71.1% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.8M | ↓ 30.9% |
Investing Cash Flow | -22.6M | ↑ 184.76% |
Financing Cash Flow | -132.0K | ↓ 100.26% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 33.4M | ↓ 1307.33% |
Investing Cash Flow | -100.4M | ↑ 344.63% |
Financing Cash Flow | 163.1M | ↓ 123697.73% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↓ 157.71% |
Investing Cash Flow | 47.7M | ↓ 147.52% |
Financing Cash Flow | 185.6M | ↑ 13.79% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↑ 30.81% |
Investing Cash Flow | -228.5M | ↓ 578.92% |
Financing Cash Flow | -4.5M | ↓ 102.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 671.0K | ↓ 90.66% |
Investing Cash Flow | -14.8M | ↓ 696.81% |
Financing Cash Flow | -1.1M | ↓ 52.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -499.0K | ↓ 174.37% |
Investing Cash Flow | 15.3M | ↓ 203.91% |
Financing Cash Flow | -1.6M | ↑ 37.61% |
Sell
Neutral
Buy
Caredx, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Caredx, Inc. | 11.61% | 126.97% | 228.09% | -63.07% | 33.83% |
![]() Idexx Laboratories, Inc. | 1.13% | -16.13% | -1.02% | -30.71% | 76.78% |
![]() Agilent Technologies Inc. | 2.42% | -8.11% | 18.01% | -22.8% | 84.96% |
![]() Thermo Fisher Scientific, Inc. | 4.08% | 2.29% | 14.99% | 7.41% | 109.35% |
![]() Danaher Corp. | 1.1% | 4.75% | 17.79% | -19.33% | 91.02% |
![]() Iqvia Holdings Inc. | 5.86% | -6.0% | 10.99% | -8.08% | 60.05% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Caredx, Inc. | NA | NA | -0.12 | 0.25 | -0.48 | -0.1 | NA | 5.03 |
![]() Idexx Laboratories, Inc. | 46.49 | 46.49 | 5.05 | 10.51 | 0.63 | 0.23 | NA | 19.16 |
![]() Agilent Technologies Inc. | 28.76 | 28.76 | 2.99 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
![]() Thermo Fisher Scientific, Inc. | 37.6 | 37.6 | 2.26 | 21.75 | 0.14 | 0.05 | 0.0 | 124.17 |
![]() Danaher Corp. | 48.58 | 48.58 | 2.63 | 7.58 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 32.24 | 32.24 | 1.22 | 11.2 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Caredx, Inc. | Buy | $1.4B | 33.83% | NA | -53.73% |
![]() Idexx Laboratories, Inc. | Buy | $38.9B | 76.78% | 46.49 | 22.34% |
![]() Agilent Technologies Inc. | Buy | $39.8B | 84.96% | 28.76 | 21.75% |
![]() Thermo Fisher Scientific, Inc. | Buy | $233.5B | 109.35% | 37.6 | 14.69% |
![]() Danaher Corp. | Buy | $192.3B | 91.02% | 48.58 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $45.2B | 60.05% | 32.24 | 9.39% |
Insights on Caredx, Inc.
Revenue is up for the last 3 quarters, 65.56M → 92.27M (in $), with an average increase of 15.5% per quarter
Netprofit is up for the last 3 quarters, -118.09M → -1.39M (in $), with an average increase of 852.0% per quarter
In the last 3 years, Caredx, Inc. has experienced a drawdown of -63.1%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 40.3%
ARK Investment Management LLC
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Bellevue Group AG
Sumitomo Mitsui Trust Holdings Inc
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Organization | Caredx, Inc. |
Employees | 635 |
CEO | Mr. Abhishek Jain |
Industry | Health Technology |
A Spac I Acquisition Corp
$27.10
-0.11%
Keyarch Acquisition Corp
$27.10
-0.11%
Connexa Sports Technologies Inc
$27.10
-0.11%
Us Value Etf
$27.10
-0.11%
First Wave Biopharma Inc
$27.10
-0.11%
Global X Msci Next Emerging
$27.10
-0.11%
Fat Projects Acquisition Corp
$27.10
-0.11%
Capital Link Global Fintech
$27.10
-0.11%
Applied Uv Inc
$27.10
-0.11%